Top in Healio: COVID-19 rebound; how PCPs can combat suicide rates

Two analyses found antiviral drugs like Paxlovid do not elevate the risk for COVID-19 rebound, contrary to previous research.
Researchers looked at 23 COVID-19 rebound studies and two phase 2/3 trials of Paxlovid (nirmatrelvir/ritonavir, Pfizer), and while some of the rebound studies showed a higher frequency of rebound among people who received antivirals, the analysis did not identify a consistent association. Further, in the Paxlovid clinical trials, COVID-19 rebound was similar between participants who received Paxlovid and those who received placebo. It was the top story on Healio last

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart